This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Seasonal Influenza industry.
What is the current market size of the seasonal influenza industry, and what growth rate is it expected to achieve?
The seasonal influenza market size has grown rapidly in recent years. It will grow from $8.41 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising prevalence of influenza, growth in the elderly population, rise in the prevalence of infectious and chronic diseases, growing burden of influenza-related illness, and rise in respiratory infections.
The seasonal influenza market size is expected to see rapid growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to increasing demand for oral drug solutions, expanding research and development activities, increasing vaccination counts, improving healthcare infrastructure, and increasing demand for retail pharmacies. Major trends in the forecast period include advancement in the treatment, advancement in technology, advancements in vaccine technology, mRNA technology, and digital health solutions for monitoring and diagnosis.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp
What are the major drivers contributing to the growth of the seasonal influenza market?
The increasing prevalence of respiratory infections is expected to propel the growth of the seasonal influenza market going forward. Respiratory infections are illnesses caused by viruses or bacteria affecting the respiratory system, including the sinuses, throat, airways, or lungs. The increasing prevalence of respiratory infections is driven by air pollution, changing climates, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated spaces. Seasonal influenza treatment helps prevent or reduce the severity of respiratory infections in several ways, primarily by addressing the influenza virus and managing symptoms that can lead to secondary infections. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, the number of tuberculosis (TB) (a respiratory infection caused by the bacterium Mycobacterium tuberculosis) cases in England experienced a 10.7% year-over-year increase in 2023, rising from 4,380 cases in 2022 to 4,850 cases. Therefore, the rise in respiratory infections will drive the growth of the seasonal influenza market.
What are the major market segments driving the growth of the seasonal influenza industry?
The seasonal influenza market covered in this report is segmented –
1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online
4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments
Subsegments:
1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes
2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata
3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus
4) By Influenza D Virus: Animal-associated Influenza D
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report
Which trends are expected to dominate the seasonal influenza market landscape in the coming years?
Major companies operating in the seasonal influenza market are focusing on advancements in treatment, such as combination vaccines, to enhance immunity by targeting multiple strains of the virus, improving effectiveness, and reducing the need for frequent vaccinations. Combination vaccines protect against multiple diseases or strains with a single injection, reducing the number of shots needed for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, its investigational combination vaccine targeting both influenza and COVID-19. Designed to enhance compliance, streamline administration, and improve convenience for individuals and healthcare systems, mRNA-1083 is being evaluated for safety and immunogenicity against standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), as well as compared to the Spikevax booster.
Who are the key market players contributing to the growth of the seasonal influenza industry?
Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.
Which regions are leading the growth of the seasonal influenza market globally?
North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Seasonal Influenza Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285
Need Customized Data On Seasonal Influenza Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
